Riociguat
- Generic Name
- Riociguat
- Brand Names
- Adempas
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19FN8O2
- CAS Number
- 625115-55-1
- Unique Ingredient Identifier
- RU3FE2Y4XI
- Background
Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pul...
- Indication
Riociguat is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
...
- Associated Conditions
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 40
- Registration Number
- NCT05825417
- Locations
- 🇬🇧
Sheffield Teaching Hospitals NHS FT, Sheffield, United Kingdom
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE
- Conditions
- Interventions
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Maastricht University
- Target Recruit Count
- 28
- Registration Number
- NCT05762146
- Locations
- 🇩🇪
University Hospital Essen, Department of Neurology, Essen, Germany
Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 15
- Registration Number
- NCT05582811
- Locations
- 🇩🇰
Danish Headache Center, Copenhagen, Glostrup, Denmark
Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Dr Sudarshan Rajagopal
- Target Recruit Count
- 15
- Registration Number
- NCT05140525
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 30
- Registration Number
- NCT04954742
- Locations
- 🇩🇪
Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital, Heidelberg, Germany
A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Actelion
- Target Recruit Count
- 47
- Registration Number
- NCT04211272
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)
- Conditions
- Interventions
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- International CTEPH Association
- Target Recruit Count
- 14
- Registration Number
- NCT03273257
- Locations
- 🇺🇸
UC San Diego, La Jolla, California, United States
🇬🇧Papworth Hospital, Cambridge, United Kingdom
🇫🇷Hopital de Bicêtre, Paris, France
Sleep-Disordered Breathing in Chronic Thromboembolic Pulmonary Hypertension
- Conditions
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 50
- Registration Number
- NCT03074539
- Locations
- 🇦🇹
Medical Unviersity Vienna, Vienna, Austria
Riociguat in Scleroderma Associated Digital Ulcers
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Dinesh Khanna, MD, MS
- Target Recruit Count
- 17
- Registration Number
- NCT02915835
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸Hospital of Special Surgery (HSS), New York, New York, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 118
- Registration Number
- NCT02744339
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.